Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2-(4-(1-oxo-2-isoindolinyl)phenyl)butyric Acid
2. Ibustrin
3. Indobufen, (+-)-isomer
4. K 3920
1. 63610-08-2
2. Ibustrin
3. Indobufen [inn]
4. K-3920
5. 2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]butanoic Acid
6. 6t9949g4lz
7. Indobufen (inn)
8. 2-(4-(1-oxoisoindolin-2-yl)phenyl)butanoic Acid
9. Benzeneacetic Acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-
10. (2s)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]butanoic Acid
11. Benzeneacetic Acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-ethyl-
12. K-2930
13. Indobufene
14. Indobufenum
15. K 3920
16. Indobufene [inn-french]
17. Indobufenum [inn-latin]
18. 2-(4-(1-oxo-2-isoindolinyl)phenyl)butyric Acid
19. (+/-)-2-[p-(1-oxo-2-isoindolinyl)phenyl]butyric Acid
20. Unii-6t9949g4lz
21. (+/-)-2-(p-(1-oxo-2-isoindolinyl)phenyl)butyric Acid
22. 36690-96-7
23. Einecs 264-364-4
24. (+/-)-indobufen
25. Enamine_001568
26. Indobufen [mi]
27. Indobufen [mart.]
28. Indobufen [who-dd]
29. Dsstox_cid_31578
30. Dsstox_rid_97463
31. Dsstox_gsid_57789
32. Oprea1_118499
33. Schembl140517
34. (+-)-2-(4-(1-oxo-2-isoindolinyl)phenyl)buttersaeure
35. Chembl1765292
36. Dtxsid7057789
37. 1-oxo-2-(p-((alpha-ethyl)carboxymethyl)phenyl)isoindoline
38. Chebi:135239
39. (+-)-2-(4-(1,3-dihydro-1-oxo-2-isoindolyl)buttersaeure
40. Hms1398h06
41. Amy33419
42. Bcp04485
43. Tox21_113871
44. Ac-672
45. Mfcd00572250
46. S5019
47. 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-benzeneacetic Acid
48. Akos015917718
49. Ccg-267421
50. Db12545
51. Ks-5220
52. Sb66092
53. Ncgc00253758-01
54. Hy-18763
55. Cas-63610-08-2
56. Cs-0014291
57. Ft-0616451
58. D07141
59. D70894
60. 610i082
61. A851741
62. J-521529
63. Q3798322
64. (+-)-2-(p-(1-oxo-2-isoindolinyl)phenyl)butyric Acid
65. 2-(4-(1-carboxypropyl)phenyl)-1-isoindolinone
66. Butyric Acid, 2-(p-(1-oxo-2-isoindolinyl)phenyl)-, (+-)-
67. 1-oxo-2-(p-((.alpha.-ethyl)carboxymethyl)phenyl)isoindoline
68. 4-(1,3-dihydro-1-oxo-(2h)-isoindol-2-yl)-alpha-ethylbenzeneacetic Acid
69. 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-ethylbenzeneacetic Acid
70. Benzeneacetic Acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-, (+-)-
71. Benzeneacetic Acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-ethyl-, (+/-)-
| Molecular Weight | 295.3 g/mol |
|---|---|
| Molecular Formula | C18H17NO3 |
| XLogP3 | 3.1 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 4 |
| Exact Mass | 295.12084340 g/mol |
| Monoisotopic Mass | 295.12084340 g/mol |
| Topological Polar Surface Area | 57.6 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 428 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Platelet Aggregation Inhibitors
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
Cyclooxygenase Inhibitors
Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)
B - Blood and blood forming organs
B01 - Antithrombotic agents
B01A - Antithrombotic agents
B01AC - Platelet aggregation inhibitors excl. heparin
B01AC10 - Indobufen
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Indobufen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Indobufen, including repackagers and relabelers. The FDA regulates Indobufen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Indobufen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Indobufen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Indobufen supplier is an individual or a company that provides Indobufen active pharmaceutical ingredient (API) or Indobufen finished formulations upon request. The Indobufen suppliers may include Indobufen API manufacturers, exporters, distributors and traders.
click here to find a list of Indobufen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Indobufen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Indobufen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Indobufen GMP manufacturer or Indobufen GMP API supplier for your needs.
A Indobufen CoA (Certificate of Analysis) is a formal document that attests to Indobufen's compliance with Indobufen specifications and serves as a tool for batch-level quality control.
Indobufen CoA mostly includes findings from lab analyses of a specific batch. For each Indobufen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Indobufen may be tested according to a variety of international standards, such as European Pharmacopoeia (Indobufen EP), Indobufen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Indobufen USP).
LOOKING FOR A SUPPLIER?
